Publisher
Springer Berlin Heidelberg
Reference12 articles.
1. Aeschlimann C, Küpfer A, Schefer H, Cerny T (1998) Comparative pharmacokinetics of oral and intravenous ifosfamide/mesna/methylene blue-therapy. The American Society for Pharmacology and Experimental Therapeutics 26:9
2. Bokemeyer C, Schmoll H-J, Ludwig E et al (1994) The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna. Br J Cancer 69:863–867
3. Brock N, Stekar J, Pohl J et al (1979) Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide. Arzneimittelforschung (Drug Res) 29:659–661
4. Hildgard P, Pohl J (1990) Oxazaphosphorine toxicity reduction by mesna. Cancer Treat Rev 17:217
5. Katz A, Epelmann S, Anelli A et al (1995) A prospective randomized evaluation of three schedules of mesna administration in patients receiving an ifosfamide-containing chemotherapy regimen: sustained efficiency and simplified administration. J Cancer Res Clin Oncol 121(2):128–131